"Conclusions:Alternatives to traditional phase II
trial design including alternative end points, randomized designs,
biomarkers, and imaging tools should allow ineffective agents to be
discarded and promising agents to undergo further investigation."
An ovarian cancer blog which includes quality resource materials: education, research, social networking, genetics and (some) healthcare politics.
“Not everything that can be counted counts and not everything that counts can be counted.”
Albert Einstein
No comments:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.